

**Table S1 – Economic outcomes in patients with and without deep SSI**

Variable	Assessment point	No deep SSI		Deep SSI		p-value
		N	Mean (SE)	n	Mean (SE)	
<b>EQ-5D-3L Utility Scores</b>	Pre-injury baseline	414	0.89 (0.01)	35	0.88 (0.03)	0.857
	Post-injury baseline	399	0 (0.01)	35	-0.03 (0.05)	0.479
	3 months	298	0.35 (0.02)	27	0.25 (0.06)	0.134
	6 months	283	0.48 (0.02)	27	0.34 (0.06)	0.038*
	9 months	274	0.53 (0.02)	23	0.46 (0.07)	0.406
	12 months	336	0.57 (0.02)	27	0.41 (0.06)	0.023*
<b>SF-6D Utility Scores</b>	Pre-injury baseline	411	0.86 (0.01)	34	0.87 (0.02)	0.629
	3 months	278	0.56 (0.01)	26	0.55 (0.02)	0.571
	6 months	263	0.61 (0.01)	26	0.57 (0.03)	0.12
	9 months	245	0.63 (0.01)	22	0.59 (0.04)	0.29
	12 months	307	0.65 (0.01)	25	0.62 (0.03)	0.372
<b>QALYs over one year follow-up</b>	EQ-5D-3L	199	0.44 (0.02)	18	0.28 (0.05)	0.01*
	SF-6D	172	0.65 (0.01)	16	0.61 (0.03)	0.211
<b>Cost of initial hospitalisation</b>		423	10318.44 (257.95)	35	9583.41 (681.97)	0.319
<b>Costs by cost category - 0-3 months</b>	Hospital inpatient care	299	808.03 (123.7)	30	1644.81 (561.3)	0.155
	Hospital outpatient care	283	599.02 (40.17)	27	641.09 (93.81)	0.683
	Community care	281	260.19 (26.17)	27	413.82 (144.17)	0.303
	Medications	272	22.51 (4.27)	27	20.95 (8.85)	0.875
	Personal social services	273	56.84 (19.3)	27	64.74 (56.2)	0.895
	Aids and adaptations	277	13.24 (1.81)	27	9.88 (3.07)	0.351
	Total	256	11303.64 (324.96)	27	12345.8 (961.4)	0.312
	<b>Costs by cost category - 3-6 months</b>	Inpatient care	279	691.37 (99.69)	28	2691.92 (965.93)
	Outpatient care	270	565.9 (36.21)	27	745.02 (110.79)	0.134
	Community care	266	247.43 (47.33)	26	354.4 (108.23)	0.371
	Medications	263	27.84 (13.8)	26	82.77 (56.21)	0.351
	Personal social services	269	124.66 (79.4)	27	0 (0)	0.118
	Aids and adaptations	265	7.77 (1.99)	27	5.58 (3.92)	0.62
	Total	250	1597.38 (158.77)	25	3542.21 (1107.79)	0.095*
<b>Costs by cost category - 6-9 months</b>	Inpatient care	271	630.91 (108.13)	23	895.57 (663.53)	0.697
	Outpatient care	260	348.75 (29.56)	22	288.74 (76.98)	0.473
	Community care	253	97.53 (15.18)	22	127.75 (45.2)	0.532
	Medications	260	20.49 (5.56)	21	25.32 (15.86)	0.777

	Personal social services	260	34.72 (14.35)	22	0 (0)	0.016*
	Aids and adaptations	256	1.45 (0.46)	22	0.46 (0.31)	0.079*
	Total	240	1091.48 (137.11)	21	623.24 (208.93)	0.068*
<b>Costs by cost category - 9-12 months</b>	Inpatient care	326	347.97 (94.16)	27	629.82 (355.52)	0.45
	Outpatient care	315	256.22 (23.56)	26	264.95 (60.44)	0.894
	Community care	315	61.77 (11.13)	25	23.05 (10.46)	0.013*
	Medications	311	19.51 (6.46)	26	27.87 (14.24)	0.596
	Personal social services	318	42.74 (18.27)	26	0 (0)	0.02*
	Aids and adaptations	316	4.08 (2.2)	26	4.82 (3.76)	0.865
	Total	296	711.58 (113.29)	25	1002.68 (424.94)	0.514
<b>Total costs over one year follow-up by cost category</b>	Inpatient care	199	2117.04 (324.48)	21	5626.42 (2099.13)	0.113
	Outpatient care	177	1803.13 (121.26)	17	1718.01 (308.45)	0.8
	Community care	168	659.45 (76.47)	16	689.4 (210.44)	0.895
	Medications	164	102.61 (27.64)	17	156.2 (98.48)	0.607
	Personal social services	166	146.48 (46.44)	17	102.82 (88.92)	0.667
	Aids and adaptations	164	28.13 (5.11)	17	25.19 (9.39)	0.785
	<b>Total costs by time period</b>	0-3 months	256	11303.64 (324.96)	27	12345.8 (961.4)
0-6 months		192	12303.94 (407.4)	24	15598.37 (1880.92)	0.099*
0-9 months		153	13350.3 (516.89)	20	16105.85 (2317.87)	0.259
0-12 months		135	13905.05 (665.81)	16	15147.28 (1746.86)	0.514

\*Statistically significant at 5% significance level

**Table S2 – Estimates of mean costs and QALY difference for patients in with deep versus no deep SSI generated from multivariate analysis adjusting for baseline demographic and clinical variables based on analysis of complete cases.**

<b>Economic outcome</b>	<b>Mean difference (95% CI)</b>	<b>p-value*</b>
QALYs - EQ-5D-3L accrued over 12 months of follow-up <sup>1,2</sup>	-0.097 (-0.205, 0.012)	0.079
QALYs - SF-6D accrued over 12 months of follow-up <sup>1,2</sup>	-0.037 (-0.094, 0.020)	0.197
Total costs incurred for the period from 0 to 3 months after randomisation <sup>1</sup>	705.01 (-2136.62, 3546.63)	0.627
Total costs incurred for the period from 0 to 6 months after randomisation <sup>1</sup>	494.03 (-2735.01, 3723.16)	0.764
Total costs incurred for the period from 0 to 9 months after randomisation <sup>1</sup>	250.86 (-3418.29, 3920.02)	0.893
Total costs incurred for the period from 0 to 12 months after randomisation <sup>1</sup>	203.45 (-4253.58, 4660.48)	0.929

\*statistically significant at 5% significance level

<sup>1</sup> model covariates were age, gender, trial site, Gustilo-Anderson wound grade, diabetes, height, weight, smoker

<sup>2</sup> In addition to the covariates in (1), measures of baseline utility were also included

95%CI = 95% confidence interval